Orthofix Medical Inc. (NASDAQ:OFIX) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Analysts give Orthofix Medical a consensus “Hold” rating: Of five covering firms, three rate the stock a buy, one a hold and one a sell. The average 12-month price target is $14.75, though recent targets were lowered to $13–$15.
• Quarterly results slightly exceeded expectations: Orthofix reported a loss of $0.39 per share versus the estimated loss of $0.41, while revenue reached $210.93 million compared with the $209.28 million consensus estimate. The company remains unprofitable, with a negative net margin of 7.41%.
• Shares remain below recent moving averages: OFIX opened at $10.01, versus 50-day and 200-day averages of $10.62 and $11.48, respectively, and has traded between $8.85 and $16.99 over the past year. Institutional investors own approximately 89.76% of the stock.

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) has been given a consensus rating of "Hold" by the five research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $14.75.

OFIX has been the topic of a number of research analyst reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Orthofix Medical in a research note on Friday, July 17th. TD Cowen reissued a "hold" rating on shares of Orthofix Medical in a research report on Thursday, May 21st. Canaccord Genuity Group cut their target price on shares of Orthofix Medical from $18.00 to $13.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Wall Street Zen cut shares of Orthofix Medical from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. Finally, Stifel Nicolaus decreased their price target on Orthofix Medical from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, May 22nd.

Orthofix Medical Stock Performance

Shares of OFIX opened at $10.01 on Friday. The business's 50 day moving average is $10.62 and its two-hundred day moving average is $11.48. Orthofix Medical has a 52-week low of $8.85 and a 52-week high of $16.99. The firm has a market cap of $407.71 million, a price-to-earnings ratio of -6.50 and a beta of 0.68. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 0.55.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical device company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.02. The business had revenue of $210.93 million during the quarter, compared to the consensus estimate of $209.28 million. Orthofix Medical had a negative net margin of 7.41% and a negative return on equity of 14.05%. Analysts forecast that Orthofix Medical will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Aviva Mcpherron sold 3,670 shares of Orthofix Medical stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.38, for a total value of $34,424.60. Following the completion of the transaction, the insider owned 66,330 shares in the company, valued at approximately $622,175.40. This trade represents a 5.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Orthofix Medical

A number of institutional investors and hedge funds have recently modified their holdings of OFIX. Juniper Investment Company LLC grew its position in shares of Orthofix Medical by 23.3% during the 4th quarter. Juniper Investment Company LLC now owns 3,510,333 shares of the medical device company's stock valued at $53,217,000 after buying an additional 663,278 shares during the last quarter. Engine Capital Management LP lifted its holdings in Orthofix Medical by 3.2% in the first quarter. Engine Capital Management LP now owns 4,390,779 shares of the medical device company's stock worth $50,362,000 after acquiring an additional 137,858 shares during the last quarter. Global Strategic Investment Solutions LLC acquired a new position in Orthofix Medical in the first quarter valued at approximately $664,000. Armistice Capital LLC boosted its stake in Orthofix Medical by 18.4% in the fourth quarter. Armistice Capital LLC now owns 2,648,000 shares of the medical device company's stock valued at $40,144,000 after acquiring an additional 412,000 shares during the period. Finally, Tejara Capital Ltd bought a new position in shares of Orthofix Medical during the second quarter valued at approximately $537,000. 89.76% of the stock is owned by institutional investors and hedge funds.

Orthofix Medical Company Profile

Orthofix Medical Inc NASDAQ: OFIX is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source